Biopharmaceutical company focused on novel antibody-based products for serious hospital-associated bacterial and fungal infections
- Year invested 2002
- Investment Stage Public/PIPES
- Sectors
- Investment Status Historic
- Website inhibitex.com
- Company Status IPO/Acquired (by Bristol Myers Squibb)